NPPB and hydrops fetalis: The PARAMOUNT-HF trial demonstrated that ARNI resulted in a lower level of N-terminal pro–B-type natriuretic peptide (NT-proBNP), a larger reduction in left atrial size, and greater improvement in the New York Heart Association (NYHA) functional class than valsartan (15).